AHNAK2 Promotes the Progression of Pancreatic Ductal Adenocarcinoma by Maintaining the Stability of c-MET

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Huang J, Lok V, Ngai CH, et al. Worldwide burden of, risk factors for, and trends in pancreatic cancer. Gastroenterology. 2021;160(3):744–754. doi:10.1053/j.gastro.2020.10.007
   PubMed Web of Science ®Google Scholar
• Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501. doi:10.1038/nature14169
   PubMed Web of Science ®Google Scholar
• Li Petri G, Cascioferro SM, El Hassouni B, et al. Biological evaluation of the antiproliferative and anti-migratory activity of a series of 3-(6-Phenylimidazo[2,1- b][1,3,4]thiadiazol-2-yl)-1 H -indole derivatives against pancreatic cancer cells. Anticancer Res. 2019;39(7):3615–3620. doi:10.21873/anticanres.13509
   PubMed Web of Science ®Google Scholar
• Carbone D, De Franco M, Pecoraro C, et al. Discovery of the 3-Amino-1,2,4-triazine-based library as selective PDK1 inhibitors with therapeutic potential in highly aggressive pancreatic ductal adenocarcinoma. Int J Mol Sci. 2023;24(4):3679. doi:10.3390/ijms24043679
   PubMed Web of Science ®Google Scholar
• Duan H, Li L, He S. Advances and prospects in the treatment of pancreatic cancer. Int J Nanomed. 2023;18:3973–3988. doi:10.2147/IJN.S413496
   PubMed Web of Science ®Google Scholar
• Yang X-Y, Y-f L, J-x X, Du Y-Z, R-s Y. Recent Advances in Well-Designed Therapeutic Nanosystems for the Pancreatic Ductal Adenocarcinoma Treatment Dilemma. Molecules. 2023;28(3):1506. doi:10.3390/molecules28031506
   PubMed Web of Science ®Google Scholar
• Komuro A, Masuda Y, Kobayashi K, et al. The AHNAKs are a class of giant propeller-like proteins that associate with calcium channel proteins of cardiomyocytes and other cells. Proc Natl Acad Sci USA. 2004;101(12):4053–4058. doi:10.1073/pnas.0308619101
   PubMed Web of Science ®Google Scholar
• Zardab M, Stasinos K, Grose RP, Kocher HM. The obscure potential of AHNAK2. Cancers. 2022;14(3):528. doi:10.3390/cancers14030528
   PubMed Web of Science ®Google Scholar
• Wang M, Li X, Zhang J, et al. AHNAK2 is a novel prognostic marker and oncogenic protein for clear cell renal cell carcinoma. Theranostics. 2017;7(5):1100–1113. doi:10.7150/thno.18198
   PubMed Web of Science ®Google Scholar
• Ye R, Liu D, Guan H, et al. AHNAK2 promotes thyroid carcinoma progression by activating the NF-κB pathway. Life Sci. 2021;286:120032. doi:10.1016/j.lfs.2021.120032
   PubMed Web of Science ®Google Scholar
• Liu G, Guo Z, Zhang Q, Liu Z, Zhu D. AHNAK2 promotes migration, invasion, and epithelial-mesenchymal transition in lung adenocarcinoma cells via the TGF-β/Smad3 pathway. Onco Targets Ther. 2020;13:12893–12903. doi:10.2147/OTT.S281517
   PubMedGoogle Scholar
• Li M, Liu Y, Meng Y, Zhu Y. AHNAK nucleoprotein 2 performs a promoting role in the proliferation and migration of uveal melanoma cells. Cancer Biother Radiopharm. 2019;34(10):626–633. doi:10.1089/cbr.2019.2778
   PubMed Web of Science ®Google Scholar
• Almeida PP, Cardoso CP, de Freitas LM. PDAC-ANN: an artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression. BMC Cancer. 2020;20(1):82. doi:10.1186/s12885-020-6533-0
   PubMed Web of Science ®Google Scholar
• Yang ZQ, Liu YJ, Zhou XL. An integrated microarray analysis reveals significant diagnostic and prognostic biomarkers in pancreatic cancer. Med Sci Monit. 2020;26:e921769. doi:10.12659/MSM.921769
   PubMed Web of Science ®Google Scholar
• Huang J, Zhou Y, Zhang H, Wu Y. A neural network model to screen feature genes for pancreatic cancer. BMC Bioinf. 2023;24(1):193. doi:10.1186/s12859-023-05322-z
   PubMed Web of Science ®Google Scholar
• Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nat Rev Cancer. 2018;18(6):341–358. doi:10.1038/s41568-018-0002-y
   PubMed Web of Science ®Google Scholar
• Modica C, Tortarolo D, Comoglio PM, Basilico C, Vigna E. MET/HGF co-targeting in pancreatic cancer: a tool to provide insight into the tumor/stroma crosstalk. Int J Mol Sci. 2018;19(12):3920. doi:10.3390/ijms19123920
   PubMed Web of Science ®Google Scholar
• Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801–1806. doi:10.1126/science.1164368
   PubMed Web of Science ®Google Scholar
• Jin H, Yang R, Zheng Z, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 2008;68(11):4360–4368. doi:10.1158/0008-5472.CAN-07-5960
   PubMed Web of Science ®Google Scholar
• Yu J, Ohuchida K, Mizumoto K, et al. Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer. World J Gastroenterol. 2006;12(24):3878–3882. doi:10.3748/wjg.v12.i24.3878
   PubMed Web of Science ®Google Scholar
• Delitto D, Vertes-George E, Hughes SJ, Behrns KE, Trevino JG. c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer. World J Gastroenterol. 2014;20(26):8458–8470. doi:10.3748/wjg.v20.i26.8458
   PubMed Web of Science ®Google Scholar
• Wang DW, Zheng HZ, Cha N, et al. Down-regulation of AHNAK2 inhibits cell proliferation, migration and invasion through inactivating the MAPK pathway in lung adenocarcinoma. Technol Cancer Res Treat. 2020;19:1533033820957006. doi:10.1177/1533033820957006
   Web of Science ®Google Scholar
• Lu Y, Xu D, Peng J, et al. HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1. EBioMedicine. 2019;44:403–418. doi:10.1016/j.ebiom.2019.05.013
   PubMed Web of Science ®Google Scholar
• Lakshmanan I, Marimuthu S, Chaudhary S, et al. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma. Oncogene. 2022;41(48):5147–5159. doi:10.1038/s41388-022-02493-6
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7(5):469–483. doi:10.1016/j.ccr.2005.04.023
   PubMed Web of Science ®Google Scholar
• Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology. 2022;163(2):386–402.e381. doi:10.1053/j.gastro.2022.03.056
   PubMed Web of Science ®Google Scholar
• Gherardi E, Sandin S, Petoukhov MV, et al. Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc Natl Acad Sci USA. 2006;103(11):4046–4051. doi:10.1073/pnas.0509040103
   PubMed Web of Science ®Google Scholar
• Moosavi F, Giovannetti E, Saso L, Firuzi O. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. Crit Rev Clin Lab Sci. 2019;56(8):533–566. doi:10.1080/10408363.2019.1653821
   PubMed Web of Science ®Google Scholar
• Xu R, Liu X, Li A, et al. c-Met up-regulates the expression of PD-L1 through MAPK/NF-κBp65 pathway. J Mol Med. 2022;100(4):585–598. doi:10.1007/s00109-022-02179-2
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang L, Peng J, et al. Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways. Biochem Pharmacol. 2022;195:114864. doi:10.1016/j.bcp.2021.114864
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xia M, Jin K, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17(1):45. doi:10.1186/s12943-018-0796-y
   PubMed Web of Science ®Google Scholar
• Li C, Wu JJ, Hynes M, et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology. 2011;141(6):2218–2227.e2215. doi:10.1053/j.gastro.2011.08.009
   PubMed Web of Science ®Google Scholar
• Pothula SP, Xu Z, Goldstein D, Pirola RC, Wilson JS, Apte MV. Targeting HGF/c-MET axis in pancreatic cancer. Int J Mol Sci. 2020;21(23):9170. doi:10.3390/ijms21239170
   PubMed Web of Science ®Google Scholar
• Luna J, Boni J, Cuatrecasas M, et al. DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth. Gut. 2019;68(8):1465–1476. doi:10.1136/gutjnl-2018-316128
   PubMed Web of Science ®Google Scholar
• Bradley CA, Salto-Tellez M, Laurent-Puig P, et al. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nat Rev Clin Oncol. 2017;14(9):562–576. doi:10.1038/nrclinonc.2017.40
   PubMed Web of Science ®Google Scholar